The Washington Post, which has famously fumed about the fact that union auto workers earn $57,000 a year, devoted a major front page story to an Indiana ironing board factory that benefits from a tariff on Chinese ironing boards that can be as high as 157 percent. The article includes several statements from economists about the unnecessarily high prices that consumers pay for ironing boards and the resulting economic distortions.

It is worth noting that the Washington Post has never once reported on the distortions created by the system of financing prescription drug research through government patent monopolies. As a result of these patent monopolies, drugs that could be profitably sold as generics for $4 a prescription are instead sold as brand name drugs for prices that can be tens or even hundreds of times higher. The mark-up on branded drugs can be equivalent to tariffs of several thousand percent.

The distortions created by patent monopolies are increased as a result of the asymmetric information in the sector. The manufacturer knows far more about its drugs than patients or doctors. This allows the manufacturer to mislead patients and doctors about the safety and effectiveness of drugs. There are more efficient ways to support research into the development of new drugs. (The government already spends $30 billion a year on bio-medical research through the National Institutes of Health.)

Given its interest in ironing boards, and the relative impact on the public's well-being of prescription drugs and ironing boards, it might be reasonable to expect that Post would at least once consider the distortions created by patent monopolies in the prescription drug industry.